Đang chuẩn bị liên kết để tải về tài liệu:
Clinical benefit of subsequent chemotherapy after drug-induced interstitial lung disease in pancreatic cancer patients: A multicenter retrospective study from Japan

Đang chuẩn bị nút TẢI XUỐNG, xin hãy chờ

Drug-induced interstitial lung disease (ILD) is not a rare adverse event in the current chemotherapy strategy for pancreatic ductal adenocarcinoma (PDAC). Thus, we aimed to find the optimal management for PDAC patients with a history of ILD induced by a gemcitabine-based regimen. |

TÀI LIỆU LIÊN QUAN

Metronomic chemotherapy with oral navelbine produces clinical benefit and low toxicity in metastatic breast cancer in K-Hospital

Survival benefit of ixazomib, lenalidomide and dexamethasone (IRD) over lenalidomide and dexamethasone (Rd) in relapsed and refractory multiple myeloma patients in routine clinical practice

Integrating economic considerations into cutpoint selection may help align clinical decision support toward value-based healthcare

Cost and economic benefit of clinical decision support systems for cardiovascular disease prevention: A community guide systematic review

Clinical benefit of immune checkpoint inhibitors approved by US Food and Drug Administration

Clinical utility gains from incorporating comorbidity and geographic location information into risk estimation equations for atherosclerotic cardiovascular disease

Clinical benefit of pembrolizumab in treatment of first line non-small cell lung cancer: A systematic review and meta-analysis of clinical characteristics

Transportation Cost and Benefit Analysis II – Air Pollution Costs

báo cáo hóa học: "Patient-reported benefit of ReSTOR® multi-focal intraocular lenses after cataract surgery: Results of Principal Component Analysis on clinical trial data"

Báo cáo khoa học: " Intensity modulated radiotherapy (IMRT) in patients with carcinomas of the paranasal sinuses: clinical benefit for complex shaped target volumes"